Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With this collection of Chronic Myeloid Leukemia (CML) related publications, we try to summarize current knowledge and address the most relevant research questions.
OPEN FOR FURTHER SUBMISSIONS - Please contact the editorial office if you feel you have a relevant article for inclusion.
To improve understanding of the pheno/genotype abnormalities associated with cancer, tests have been developed to identify and quantify residual cancer cells undetected by conventional methods, with the hope of providing clinically meaningful predictive and/or prognostic data to inform therapy decision-making. This collection features critical analyses of the extent to which this has been achieved
This Emerging Leaders collection acknowledges and showcases the latest research from groundbreaking researchers, clinicians, and educators who are still in the early stages of their scientific careers.
Follow our checklist to avoid common mistakes to help get your manuscript to journal editors faster. We also offer a FREE language check from our partner AJE.
The World Health Organization (WHO) Classification of Tumours provides a definitive classification of all tumours, worldwide. This is essential to underpin the diagnosis and treatment of cancer, as well as research and education. Without it, clinical trial results could not be compared between countries, research results could not be evaluated collectively and epidemiological studies based on cancer registration would be impossible. The classification will help move the field forward by being based on a forwardlooking multidisciplinary effort grounded in genetic advances, with an eye on worldwide applicability.
An overview of the classification and its salient features are provided in two typescripts, which cover the classification of myeloid and histiocytic/dendritic neoplasms and the classification of lymphoid neoplasms.
Added to this is the recent 'HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions'. In this typescript a group of experts under auspices of the Human Genome Organization’s (HUGO) Gene Nomenclature Committee (HGNC) proposes using double colons (::) as the official designation for fusion genes. The Leukemia Editors strongly support the HGNC recommendation and request authors use the HGNC nomenclature in submissions to Leukemia and other journals. The goal of HUGO and HGNC is to provide unique symbols and names for human gene loci including protein coding genes, non-coding RNA genes and pseudogenes with the purpose of unambiguous scientific communication.